TSHA | tickerfilter.com

Fundamental analysis

20%

Profitability 18%

Dept financing 24%

Liquidity 50%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

1.64%

1 Month

-38.00%

3 Months

-10.14%

6 Months

-14.29%

1 Year

7.20%

2 Year

-2.62%

Key data

Stock price

$1.75

P/E Ratio

-4.02

DAY RANGE

$1.73 - $1.92

EPS

-$0.57

52 WEEK RANGE

$1.36 - $4.31

52 WEEK CHANGE

$5.08

MARKET CAP

459.073 M

YIELD

N/A

SHARES OUTSTANDING

204.943 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/12/2024

BETA

2.10

PUBLIC FLOAT

AVERAGE 10 VOLUME

$2,658,340

AVERAGE 30 VOLUME

$3,767,697

Company detail

CEO: R. A. Session
Region: US
Website: tayshagtx.com
Employees: 180
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Taysha Gene Therapies, Inc. focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company was incorporated in 2019 and is based in Dallas, Texas.

TSHA - Taysha Gene Therapies, Inc.